VTVT logo

vTv Therapeutics Inc

VTVT

Build a strategy around VTVT

Accountable AI Logo

vTv Therapeutics Inc AI Insights

Informational only. Not investment advice.
As of 2025-12-09

Snapshot

  • Cash of 98.5M covers 4.7 years of burn at current -20.8M FCF TTM rate - extended runway post 77.5M equity raise[Cash and Equivalents]
  • Revenue collapsed 80% over 3Y to just 17K TTM - essentially zero commercial operations, pure R&D play[Total Revenue 3Y Growth]
  • R&D spend of 16.2M TTM is 54% of total opex - clinical-stage biotech with no marketed products[Research and Development]

Watch Triggers

  • Cash and Equivalents: Falls below 40M (2yr runway)Triggers dilutive financing or strategic alternatives discussion
  • Research and Development: Increases >50% without revenueAccelerated burn signals late-stage trials or desperation spend
  • Total Revenue: Any material increase above 1MWould indicate partnership deal or licensing milestone - thesis changer

Bull Case

Strong balance sheet with 98.5M cash, minimal debt (360K, 0.5% D/E), and 4.7yr runway provides time for pipeline maturation without near-term dilution

Cash and EquivalentsDebt to EquityFree Cash Flow

Trading at 3.7x book vs tangible equity of 70.5M - limited downside to cash value if pipeline fails

P/B RatioTangible Book ValueMarket Cap

Bear Case

Zero commercial revenue (17K TTM) with -80% 3Y decline means 100% dependent on pipeline success - binary risk profile

Total RevenueTotal Revenue 3Y Growth

Burning 20.8M annually with no path to profitability - eventual dilution or failure inevitable without clinical wins

Free Cash FlowNet IncomeOperating Income

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
35%

Leverage VTVT's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Binary outcome: pipeline success or cash depletion by 2030 at current burn rate

3-5ymed
  • 4.7 year cash runway at -20.8M annual burn
  • Zero revenue generation capability
  • Clinical trial outcomes will determine survival
Cash 98.5M vs FCF -20.8M TTMRevenue 17K TTM (negligible)R&D 16.2M TTM ongoing spend

Valuation Context

Caveats

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.